VRS Vaccine Protection for Seniors: Latest Research
- A new study indicates that a single dose of the respiratory syncytial virus (VRS) vaccine can protect older adults for two consecutive cold adn flu seasons, potentially reducing...
- A study published August 30, 2024, in the Journal of the American Medical association (JAMA) found that VRS vaccination reduced the risk of VRS-related hospitalization in older adults...
- Wesley Self, the study's principal investigator and senior vice president of clinical research at Vanderbilt University Medical Center, emphasized the public health significance of these findings, stating that...
Okay, I will rewrite the provided text into a well-sourced, evergreen article, adhering too all the guidelines you’ve specified.
VRS vaccine Shows Promise for Multi-Season Protection in Older Adults
Table of Contents
A new study indicates that a single dose of the respiratory syncytial virus (VRS) vaccine can protect older adults for two consecutive cold adn flu seasons, potentially reducing hospitalizations.
Study Details Vaccine Effectiveness Over two Seasons
A study published August 30, 2024, in the Journal of the American Medical association (JAMA) found that VRS vaccination reduced the risk of VRS-related hospitalization in older adults by 58% over two seasons. The study analyzed data from nearly 7,000 individuals over 60 years old who were hospitalized for respiratory illnesses across 26 hospitals in 20 states during the 2023-2024 and 2024-2025 seasons.
Dr. Wesley Self, the study’s principal investigator and senior vice president of clinical research at Vanderbilt University Medical Center, emphasized the public health significance of these findings, stating that the vaccine demonstrably helps prevent serious VRS-related illness and hospitalizations in the elderly.
Protection Wanes,Raising Questions About Booster Doses
While the study demonstrated important protection,the vaccine’s effectiveness decreased between the first and second seasons. The protection against VRS-related hospitalizations was 69% in the first year but declined to 48% in the second year. This decrease raises questions about the potential need for booster doses to maintain long-term protection.
VRS Impact on Older Adults
VRS poses a significant health risk to adults aged 60 and older, especially during the autumn and winter months. Researchers estimate that VRS causes up to 150,000 hospitalizations and 8,000 deaths annually in the United States.
Current CDC Recommendations
The Centers for Disease Control and Prevention (CDC) currently recommends a single dose of the VRS vaccine for adults aged 75 years and older, and also for those between 50 and 74 years old who are at high risk of serious illness. The CDC does not currently consider the VRS vaccine to be an annual vaccination, and individuals who have already received a dose are not immediately recommended to receive another.
Future Research and Guidelines May Evolve
The findings of this study may prompt a review of current vaccination guidelines. Dr. Self suggested that administering a second dose after a certain interval could potentially prolong protection. Further research is needed to evaluate the duration of protection following the initial dose and to determine whether repeat vaccinations should be recommended in the future.